41 assets in Carcinoma Of Esophagus

Therapeutic assets addressing Carcinoma Of Esophagus, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Pembrolizumab Carcinoma Of Esophagus	NuCana plc	P3	BB (69)
Docetaxel Carcinoma Of Esophagus	NuCana plc	P3	BB (64)
Binimetinib Carcinoma Of Esophagus	National Cancer Institute (NCI)	P2	CCC (53)
Capivasertib Carcinoma Of Esophagus	National Cancer Institute (NCI)	P2	CCC (53)
Crizotinib Carcinoma Of Esophagus	National Cancer Institute (NCI)	P2	CCC (53)
Dabrafenib Carcinoma Of Esophagus	National Cancer Institute (NCI)	P2	CCC (53)
Dasatinib Carcinoma Of Esophagus	National Cancer Institute (NCI)	P2	CCC (53)
Defactinib Carcinoma Of Esophagus	National Cancer Institute (NCI)	P2	CCC (53)
Fexagratinib Carcinoma Of Esophagus	National Cancer Institute (NCI)	P2	CCC (53)
Gsk-2636771 Carcinoma Of Esophagus	National Cancer Institute (NCI)	P2	CCC (53)
Ipatasertib Carcinoma Of Esophagus	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Carcinoma Of Esophagus	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Carcinoma Of Esophagus	Mayo Clinic	P2	CCC (53)
Olanzapine Carcinoma Of Esophagus	OHSU Knight Cancer Institute	P2	CCC (53)
Osimertinib Carcinoma Of Esophagus	National Cancer Institute (NCI)	P2	CCC (53)
Palbociclib Carcinoma Of Esophagus	National Cancer Institute (NCI)	P2	CCC (53)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 Carcinoma Of Esophagus	National Cancer Institute (NCI)	P2	CCC (53)
Pertuzumab Carcinoma Of Esophagus	National Cancer Institute (NCI)	P2	CCC (53)
Relatlimab Carcinoma Of Esophagus	National Cancer Institute (NCI)	P2	CCC (53)
Sapanisertib Carcinoma Of Esophagus	National Cancer Institute (NCI)	P2	CCC (53)
Thalidomide Carcinoma Of Esophagus	Henan Cancer Hospital	P2	CCC (53)
Trametinib Carcinoma Of Esophagus	National Cancer Institute (NCI)	P2	CCC (53)
Trastuzumab Carcinoma Of Esophagus	National Cancer Institute (NCI)	P2	CCC (53)
Trastuzumab Emtansine Carcinoma Of Esophagus	National Cancer Institute (NCI)	P2	CCC (53)
Ulixertinib Carcinoma Of Esophagus	National Cancer Institute (NCI)	P2	CCC (53)
Vismodegib Carcinoma Of Esophagus	National Cancer Institute (NCI)	P2	CCC (53)
Adavosertib Carcinoma Of Esophagus	National Cancer Institute (NCI)	P2	CCC (52)
Taselisib Carcinoma Of Esophagus	National Cancer Institute (NCI)	P2	CCC (51)
Copanlisib Carcinoma Of Esophagus	National Cancer Institute (NCI)	P2	CCC (49)
Bms-986504 Carcinoma Of Esophagus	Northwestern University	P1/2	CCC (48)
ctx131 Carcinoma Of Esophagus	CRISPR Therapeutics AG	P1/2	CCC (48)
Cis-Diamminedichloroplatinum Ii Carcinoma Of Esophagus	National Cancer Institute (NCI)	P1	CC (43)
Elimusertib Carcinoma Of Esophagus	National Cancer Institute (NCI)	P1	CC (43)
Fludeoxyglucose Carcinoma Of Esophagus	Jonsson Comprehensive Cancer Center	P1	CC (43)
Carboplatin Carcinoma Of Esophagus	National Cancer Institute (NCI)	P1	CC (41)
Veliparib Carcinoma Of Esophagus	National Cancer Institute (NCI)	P1	CC (41)
Fosifloxuridine Nafalbenamide Carcinoma Of Esophagus	NuCana plc	P1/2	CC (40)
89zr-dfo-n-suc-c9scfv Carcinoma Of Esophagus	Var2 Pharmaceuticals	Early P1	C (39)
89Zr-DFO-N-Suc-F8scFv Carcinoma Of Esophagus	Var2 Pharmaceuticals	Early P1	C (39)
Fluorouracilum Carcinoma Of Esophagus	Alliance for Clinical Trials in Oncology	N/A	D (30)
Oxaliplatin Carcinoma Of Esophagus	Alliance for Clinical Trials in Oncology	N/A	D (30)